AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03018951 — intervention group
Intervention type: OTHER
Intervention: Pilot Test 2 assessment session
Description: Consenting participants will engage in a one off assessment session where the revised specialist tool to assess frailty in older adults with a diagnosis of functional mental illness will be administered. The administration of the tool will follow the same process as in pilot test 1. Participants will then be asked to complete a further self-rated frailty assessment tool: the Tilburg Frailty Indicator. Again, following the administration of the tools, qualitative data will be gathered from the participant to establish the comprehensibility, relevance, acceptability and feasibility of the revised tool as per the methods in pilot test 1. The tool will be scored by a study researcher and the study's chief investigator at the same time to assess inter-rater reliability. The duration of the assessment session will be 90 minutes maximum.
Study NCT04603638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: 40 mg/kg(peroperative), 40 mg/kg (postoperative 12 h)
Study NCT04603638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic
Description: 100 ml
Study NCT04637178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance training sessions twice a week for ten weeks
Study NCT04637178 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Endurance training (habitual)
Description: Endurance training for ten weeks (habitual routines)
Study NCT04637178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance training (habitual)
Description: Endurance training for ten weeks (habitual routines)
Study NCT03785171 — intervention group
Intervention type: PROCEDURE
Intervention: surgical revascularization
Description: Indirect revascularization procedure
Study NCT03038438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abre venous self-expanding stent system
Description: venous stent
Study NCT00355199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab-HDS
Description: Rituximab-HDS
Study NCT00355199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab-CHOP
Description: Rituximab-CHOP
Study NCT02952807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: vaginal Misoprostol Plus Foley Catheter
Study NCT02952807 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley Catheter
Study NCT02183051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg
Study NCT02183051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 3.75 mg
Study NCT02183051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 1.875 mg
Study NCT02183051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 200 mg
Study NCT02183051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02183051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02183051 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02183051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg
Study NCT02183051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg
Study NCT06283368 — intervention group
Intervention type: PROCEDURE
Intervention: Thyroidectomy, Bilaterally Total
Description: Thyroidectomy, Bilaterally Total
Study NCT06283368 — intervention group
Intervention type: PROCEDURE
Intervention: Thyroidectomy, Unilaterally Total
Description: Thyroidectomy, Unilaterally Total
Study NCT06283368 — intervention group
Intervention type: PROCEDURE
Intervention: Thyroidectomy, Complementary
Description: Thyroidectomy, Complementary
Study NCT06283368 — intervention group
Intervention type: PROCEDURE
Intervention: Thyroidectomy, Near Total
Description: Thyroidectomy, Near Total
Study NCT00653445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 40mg
Study NCT00653445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: 10mg
Study NCT05823831 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Brief Infant-Toddler Social and Emotional Assessment (BITSEA) questionnaire
Description: Brief Infant-Toddler Social and Emotional Assessment (BITSEA) questionnaire was used to assess children's social-emotional development.
Study NCT05823831 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Brief Infant Sleep Questionnaire (BISQ) questionnaire
Description: A brief Infant Sleep Questionnaire (BISQ) was used to assess children's sleep.
Study NCT05823831 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multidimensional Scale of Perceived Social Support (MSPSS) questionnaire
Description: A Multidimensional Scale of Perceived Social Support (MSPSS) questionnaire was used to evaluate maternal social support.
Study NCT05823831 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Brief Symptom Inventory (BSI) questionnaire
Description: A brief Symptom Inventory (BSI) questionnaire was used to evaluate psychological distress.
Study NCT01944371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.
Study NCT00069108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 FU
Description: As prescribed, in 2 week cycles
Study NCT00069108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: As prescribed, in 2 week cycles
Study NCT00069108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: As prescribed, in 3 week cycles
Study NCT00069108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: As prescribed, in 2 week cycles
Study NCT00069108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1000mg/m2 po bid on days 1-15 of each 3 week cycle
Study NCT04413773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual + Video
Description: Additionally to treatment as usual a video is shown to participant about procedures on the ward before, during and after surgery
Study NCT04413773 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Explanation of standard procedures before, during and after surgery by nurse
Study NCT01453803 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Harvesting and Implantation of Adipose-Derived Stem Cells
Description: The adipose tissue specimen will be collected from the patient's abdomen or applicable region using a liposuction cannula. The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred for catheter injection.
Study NCT02873091 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia
Study NCT02873091 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous epidural infusion
Study NCT02873091 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent epidural bolus
Study NCT02873091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Study NCT02873091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sufentanil
Study NCT03773315 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UMH extract
Description: Schisandra chinensis extract 500 mg/day for 12 weeks
Study NCT03773315 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch placebo 500 mg/day for 12 weeks
Study NCT00969527 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oncoxin + Viusid
Description: 50 ml of Oncoxin + Viusid (Orally administered) twice a day, for 12 weeks.
Study NCT00969527 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 ml of Placebo (orally administered) twice a day, for 12 weeks.
Study NCT03801122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Administration of tranexamic acid, with 3 injections/8 hours.
Study NCT03017300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold IMT®
Description: A device used to offer threshold load to inspiratory muscle
Study NCT03017300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFLEX®
Description: A device used to offer resisive to inspiratory muscle
Study NCT03226951 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subthreshold 532nm laser
Description: Subthershold 532nm laser
Study NCT01143779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLT-PET
Description: FLT-PET scan uses the FLT solution (dosage of FLT in range between 1 and 10 mCi) with imaging performed 60-90 minutes after FLT intravenous injection.
Study NCT02811731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 16/5mg - B
Study NCT02811731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan 16mg and Amlodipine 5mg
Study NCT02674815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training Exercise programme
Description: High intensity interval training (HIIT) requires participants to exercise at high levels of VO2peak (≥80% VO2peak). Participants exercise for short periods (e.g. 15-30 seconds) followed by periods of rest (active or passive) and typically continue this pattern for a set time period or until exhaustion.
Study NCT03896204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone-suppoted joint protection technique
Description: After joint protection technics training, patients will be followed up with telephone support for 1 month.
Study NCT03896204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: joint protection technique training
Description: Training will be given to individuals about joint protection technique
Study NCT02938299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19IL2 + L19TNF
Description: Mixture of L19IL2 and L19TNF once weekly
Study NCT02938299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical resection of melanoma tumor lesions
Study NCT02938299 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgical resection of melanoma tumor lesions
Study NCT02077010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nebulized milrinone
Description: inhaled nebulized milrinone 60mg/4ml
Study NCT04474834 — intervention group
Intervention type: GENETIC
Intervention: Polygenic Risk Score
Description: A Polygenic Risk Score (PRS) is a blood based genetic test which assesses 300 common breast cancer susceptibility loci (Single Nucleotide Polymorphisms). The PRS has been retrospectively validated and categorizes women into three categories of lifetime risk of developing breast cancer: Low Risk (\<15% lifetime risk), Above Average Risk (15 to 40%), and high risk (>40 %).
Study NCT04323124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07059013
Description: Participants will recieve PF-07059013
Study NCT04323124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will recieve placebo
Study NCT03995134 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Propofol and Remifentanil administered by TCI pump
Description: Propofol, Remifentanil, Alaris PK (pharmacokinetic) infusion pump with TCI
Study NCT02201953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily
Study NCT02201953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: 400 mg tablet administered orally once daily
Study NCT02201953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT04789772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Description: The interventional group receive laser acupuncture applied on acupoints of PC6 (Neiguan), HT7 (Shenmen), LI4 (Hegu), ST36 (Zusanli), SP6 (Sanyinjiao), and LR3 (Taichong).
Study NCT00577473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mesalamine
Description: mesalamine 2.4 g/day (400 mg tablet) for 6 weeks
Study NCT00508794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Group
Description: 3 sessions of yoga each week for 6 weeks.
Study NCT00508794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stretching Control Group
Description: 3 sessions of stretching each week for 6 weeks
Study NCT00508794 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist Control Group
Description: Option of participating in the yoga or stretching program after the study has ended.
Study NCT00508794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
Study NCT00508794 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
Study NCT03889808 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of serum anti-toxin Abs for C. difficile
Study NCT02202421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Applied Behavior Analysis (T-ABA)
Description: Participants will be enrolled in a five week Targeted Applied Behavior Analysis (T-ABA) parent therapy group. T-ABA parent groups will be 1.5 hours in length. Following the five weeks of parent group sessions, parents will participate in five weekly one-hour parent-therapist sessions in which a therapist will work one-on-one with the parent and their child. One treatment group (T-ABA Parent Group plus Individual Therapy) will also receive eight one-hour individual therapist-child applied behavior analysis therapy sessions concurrent with the parent group and parent-therapist sessions. The second treatment group (T-ABA Parent Training Only) will be offered eight one hour individual therapist-child applied behavior analysis sessions at the conclusion of the study if desired.
Study NCT02202421 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Targeted Applied Behavior Analysis (T-ABA)
Description: Participants will be enrolled in a five week Targeted Applied Behavior Analysis (T-ABA) parent therapy group. T-ABA parent groups will be 1.5 hours in length. Following the five weeks of parent group sessions, parents will participate in five weekly one-hour parent-therapist sessions in which a therapist will work one-on-one with the parent and their child. One treatment group (T-ABA Parent Group plus Individual Therapy) will also receive eight one-hour individual therapist-child applied behavior analysis therapy sessions concurrent with the parent group and parent-therapist sessions. The second treatment group (T-ABA Parent Training Only) will be offered eight one hour individual therapist-child applied behavior analysis sessions at the conclusion of the study if desired.
Study NCT00199381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline
Description: Oral istradefylline (KW-6002) 20 or 40 mg once daily.
Study NCT03887923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular Physical Therapy
Description: Balance, Gaze Stabilization, Habituation, and Walking exercises
Study NCT03406377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPK-88003
Description: OPK-88003 subcutaneous injection
Study NCT03406377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study NCT00385671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine hydrochloride
Description: Duloxetine (DLX) once daily (QD), orally (PO)
Study NCT00385671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: Pregabalin (PGB) orally (PO)
Study NCT00385671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin
Description: Stable Gabapentin (GAB) (participants will remain on the same dose of gabapentin at which they entered the study)
Study NCT01586364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene 60Mg Oral Tablet
Study NCT02363920 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HOF
Description: the addition of high oxygen flow to patients breathing spontaneously
Study NCT02363920 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: HOF
Description: the addition of high oxygen flow to patients breathing spontaneously
Study NCT02363920 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive mechanical ventilation (NIV)
Description: the addition of a ventilatory support delivered with a oro-nasal interface
Study NCT02363920 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: noninvasive mechanical ventilation (NIV)
Description: the addition of a ventilatory support delivered with a oro-nasal interface
Study NCT03198715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS1040b
Description: DS-1040b in solution for intravenous infusion
Study NCT03198715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution for intravenous infusion
Study NCT00092417 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Varicella Zoster Virus Vaccine
Description: Single 0.65 mL subcutaneous injection of higher potency zoster vaccine (\~207,000 plaque-forming units \[PFU\]/0.65-mL dose)
Study NCT00092417 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Varicella Zoster Virus Vaccine
Description: Single 0.65 mL subcutaneous injection of lower potency zoster vaccine (\~58,000 plaque-forming units \[PFU\]/0.65-mL dose)
Study NCT02769117 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound on fractured bone
Description: A new ultrasound technique for children and adults who have sustained forearm or clavicle fractures
Study NCT02769117 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound on contralateral intact bone
Description: A new ultrasound technique for the intact bone as the control for children and adults who have sustained forearm or clavicle fractures
Study NCT04436354 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vaginoscopic office hysteroscopy
Description: comparison of procedural time and pain scores of patients in different gynecologycal positions
Study NCT04230889 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Diet Group
Description: three main meals and two snacks
Study NCT04230889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 1 Nutritional Shake
Description: 2 servings per day
Study NCT04230889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2 Nutritional Shake
Description: 2 servings per day
Study NCT03549936 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low lactose or regular formula
Description: If infant is not breast feeding and parents plan to formula feed, following written informed consent, infant is randomized to receive low lactose formula or regular formula which arrives from milk lab blinded and labeled as formula A or formula B.
Study NCT02273479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin®
Description: Asasantin® extended release (RAD-SP)
Study NCT02273479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01600326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tenotomy (no injection)
Description: Subjects randomized to this group will fill out a pre-treatment pain survey and have a blood draw They will be be contacted by the investigator by telephone or email on day 7 and day 14 to complete another pain survey. Subjects must avoid non steroidal anti-inflammatory medications for 2 weeks before the study. Two weeks after enrollment subjects see their referring physician to begin physical therapy.
Study NCT01600326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided platelet rich plasma injection
Description: Subjects will fill out a pre-treatment pain survey, then will undergo ultrasound and have blood drawn from their arm.~The blood sample will be separated into blood cells and plasma. The plasma portion of the blood (liquid minus the cells) will be injected into the tendon under sterile conditions. Ultrasound will help guide the injection. This is called Ultrasound guided platelet rich plasma injection.~Subjects will be be contacted by the investigator by telephone or email on day 7 and day 14 to complete another pain survey. Subjects must avoid non steroidal anti inflammatory medications for 2 weeks before the study and 2 weeks after the study.~Subjects will see their referring physician two weeks after treatment to begin physical therapy.